98%
921
2 minutes
20
The mu1 opioid receptor gene, OPRM1, has long been a high-priority candidate for human genetic studies of addiction. Because of its potential functional significance, the non-synonymous variant rs1799971 (A118G, Asn40Asp) in OPRM1 has been extensively studied, yet its role in addiction has remained unclear, with conflicting association findings. To resolve the question of what effect, if any, rs1799971 has on substance dependence risk, we conducted collaborative meta-analyses of 25 datasets with over 28,000 European-ancestry subjects. We investigated non-specific risk for "general" substance dependence, comparing cases dependent on any substance to controls who were non-dependent on all assessed substances. We also examined five specific substance dependence diagnoses: DSM-IV alcohol, opioid, cannabis, and cocaine dependence, and nicotine dependence defined by the proxy of heavy/light smoking (cigarettes-per-day >20 vs. ≤ 10). The G allele showed a modest protective effect on general substance dependence (OR = 0.90, 95% C.I. [0.83-0.97], p value = 0.0095, N = 16,908). We observed similar effects for each individual substance, although these were not statistically significant, likely because of reduced sample sizes. We conclude that rs1799971 contributes to mechanisms of addiction liability that are shared across different addictive substances. This project highlights the benefits of examining addictive behaviors collectively and the power of collaborative data sharing and meta-analyses.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752855 | PMC |
http://dx.doi.org/10.1007/s10519-015-9737-3 | DOI Listing |
Front Public Health
September 2025
Department of Medicine, University of Chicago, Chicago, IL, United States.
Background: Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV-S) is a research project funded by the National Institute for Drug Abuse to implement and evaluate multi-level interventions to decrease barriers to substance use screening and treatment for PLWH. At its center is a multidomain intervention addressing digital, sociocultural, and health care system environments, at individual, interpersonal, and community levels. ePORTAL HIV-S has four overall goals; this manuscript describes the protocol specifically for the randomized control trial (RCT) portion of the study.
View Article and Find Full Text PDFAlpha Psychiatry
August 2025
Department of Addictology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic.
Objective: Information about the level of general personality functioning could provide benefits for tailoring substance use disorder (SUD) treatment. This study examined self-reported personality functioning among patients with SUD compared to the general population, gender specifics, and the psychometric properties of the Czech Level of Personality Functioning Scale-Self Report (LPFS-SR).
Methods: Two samples were used in this study.
Cell Physiol Biochem
September 2025
Zoology Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Background/aims: Drug addiction is a neuropsychiatric disorder characterised by compulsive drug-seeking behaviour notwithstanding adverse consequences. This work seeks to address a deficiency in the literature by comparing drug-addicted and non-addicted individuals within an Iraqi population through the analysis of a 1000-base pair variable number of tandem repeats (VNTRs) polymorphism of the dopamine receptor gene DRD4. The association of this novel polymorphism with drug addiction has not yet been examined.
View Article and Find Full Text PDFAm J Psychiatry
September 2025
Michigan Innovations in Addiction Care Through Research and Education (MI-ACRE) Program, Department of Psychiatry, University of Michigan, Ann Arbor.
Objective: While opioid overdose has begun to decrease in recent years, stimulant overdose has continued to increase and has not been adequately addressed. Unlike opioid use disorder, there are no medications approved by the U.S.
View Article and Find Full Text PDFSubst Abuse Treat Prev Policy
September 2025
Centre for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, 20246, Hamburg, Germany.
Background: Alcohol use disorder (AUD) is conceptualized as a dimensional phenomenon in the DSM-5, but electronic health records (EHRs) rely on binary AUD definitions according to the ICD-10. The present study classifies AUD severity levels using EHR data and tests whether increasing AUD severity levels are linked with increased comorbidity.
Methods: Billing data from two German statutory health insurance companies in Hamburg included n = 21,954 adults diagnosed with alcohol-specific conditions between 2017 and 2021.